75 related articles for article (PubMed ID: 23153123)
1. The use of photodynamic therapy in the treatment of lentigo maligna.
Karam A; Simon M; Lemasson G; Misery L
Pigment Cell Melanoma Res; 2013 Mar; 26(2):275-7. PubMed ID: 23153123
[No Abstract] [Full Text] [Related]
2. Treatment of lentigo maligna with tazarotene 0.1% gel.
Chimenti S; Carrozzo AM; Citarella L; De Felice C; Peris K
J Am Acad Dermatol; 2004 Jan; 50(1):101-3. PubMed ID: 14699375
[TBL] [Abstract][Full Text] [Related]
3. Treatment of lentigo maligna with topical 1% cidofovir.
Calista D
Br J Dermatol; 2007 Aug; 157(2):421-3. PubMed ID: 17596162
[No Abstract] [Full Text] [Related]
4. Recurrent lentigo maligna melanoma: regression associated with local azelaic acid 20%.
Vereecken P; Heenen M
Int J Clin Pract; 2002; 56(1):68-9. PubMed ID: 11831841
[TBL] [Abstract][Full Text] [Related]
5. Image in clinical medicine. Lentigo maligna.
Noel B; Kunzle N
N Engl J Med; 2005 Nov; 353(20):2176. PubMed ID: 16291987
[No Abstract] [Full Text] [Related]
6. [Topical imiquimod as palliative therapy for extensive lentigo maligna on the cheek].
Cheikhrouhou H; Pouaha J; Claeys A; Truchetet F
Ann Dermatol Venereol; 2010 Feb; 137(2):142-4. PubMed ID: 20171439
[No Abstract] [Full Text] [Related]
7. Intralesional interferon treatment of lentigo maligna.
Cornejo P; Vanaclocha F; Polimon I; Del Rio R
Arch Dermatol; 2000 Mar; 136(3):428-30. PubMed ID: 10724220
[No Abstract] [Full Text] [Related]
8. A novel two-stage treatment of lentigo maligna using ablative laser therapy followed by imiquimod.
de Vries K; Rellum R; Habets JM; Prens EP
Br J Dermatol; 2013 Jun; 168(6):1362-4. PubMed ID: 23252724
[No Abstract] [Full Text] [Related]
9. Management of lentigo maligna and lentigo maligna melanoma: seminars in surgical oncology.
Arlette JP; Trotter MJ; Trotter T; Temple CL
J Surg Oncol; 2004 Jul; 86(4):179-86. PubMed ID: 15221924
[TBL] [Abstract][Full Text] [Related]
10. Five-year recurrence rate of lentigo maligna after off-label treatment with imiquimod.
Cliff SH
Br J Dermatol; 2016 Jan; 174(1):22-3. PubMed ID: 26790655
[No Abstract] [Full Text] [Related]
11. Imiquimod treatment of lentigo maligna: an open-label study of 34 primary lesions in 32 patients.
Buettiker UV; Yawalkar NY; Braathen LR; Hunger RE
Arch Dermatol; 2008 Jul; 144(7):943-5. PubMed ID: 18645150
[No Abstract] [Full Text] [Related]
12. Extensive lentigo maligna clearing with topical imiquimod.
Epstein E
Arch Dermatol; 2003 Jul; 139(7):944-5. PubMed ID: 12873903
[No Abstract] [Full Text] [Related]
13. [How I treat ... lentigo maligna by topical imiquimod].
Bourguignon R; Paquet P; Quatresooz P; Piérard GE
Rev Med Liege; 2005 Sep; 60(9):691-4. PubMed ID: 16265961
[TBL] [Abstract][Full Text] [Related]
14. Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream.
Chapman MS; Spencer SK; Brennick JB
Arch Dermatol; 2003 Jul; 139(7):943-4. PubMed ID: 12873902
[No Abstract] [Full Text] [Related]
15. Imiquimod use in the treatment of lentigo maligna.
Junkins-Hopkins JM
J Am Acad Dermatol; 2009 Nov; 61(5):865-7. PubMed ID: 19836644
[TBL] [Abstract][Full Text] [Related]
16. Remission of extensive lentigo maligna after treatment with imiquimod.
Piazza CD; Sampaio SA
An Bras Dermatol; 2009; 84(1):82-4. PubMed ID: 19377765
[TBL] [Abstract][Full Text] [Related]
17. Lentigo maligna: one size does not fit all.
Bowen GM; Bowen AR; Florell SR
Arch Dermatol; 2011 Oct; 147(10):1211-3. PubMed ID: 22006139
[No Abstract] [Full Text] [Related]
18. Imiquimod 5% cream in occlusion, for the treatment of lentigo maligna: A new scheme of short cycles and the need for clinical trials.
Astorino S; Astorre P; Pasquini P; Di Nunno D; Pellegrini F; Paolino G
Dermatol Ther; 2019 Jan; 32(1):e12757. PubMed ID: 30285299
[No Abstract] [Full Text] [Related]
19. Lentigo maligna and radiotherapy.
Wilson LD
N Engl J Med; 2006 Mar; 354(12):1322; author reply 1322. PubMed ID: 16554541
[No Abstract] [Full Text] [Related]
20. Ingenol mebutate to treat lentigo maligna of the head (face and scalp): A prospective, multicenter, single-arm phase 2 trial indicates no benefit.
Montaudié H; Le Duff F; Butori C; Hofman V; Fontas E; Roger-Cruzel C; Bahadoran P; Perrot JL; Desmedt E; Legoupil D; Passeron T; Lacour JP
J Am Acad Dermatol; 2020 Mar; 82(3):731-733. PubMed ID: 31325551
[No Abstract] [Full Text] [Related]
[Next] [New Search]
